YL 202
Alternative Names: BNT-326; YL-202Latest Information Update: 28 Oct 2024
At a glance
- Originator MediLink Therapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
- Phase I HER2 negative breast cancer; Non-small cell lung cancer
Most Recent Events
- 25 Sep 2024 MediLink Therapeutics re-initiates a phase I trial in HER2-negative-breast-cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) and Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater)in China and USA (IV) (NCT05653752)
- 17 Jun 2024 US FDA places partial clinical hold on a phase I trial in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA and China (IV) (NCT05653752)
- 03 Jun 2024 MediLink Therapeutics plans a phase II trial for Breast cancer (Metastatic disease, Late-stage disease, Inoperable/Unresectable) in China (IV, Infusion) (NCT06439771)